Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder

Samsung Medical Center2,985 enrolled

Overview

Newly diagnosed NMOSD patients

From 2011 to 2022, newly diagnosed NMOSD patients who had not previously claimed NMOSD. Exclusion criteria were history of cancer or had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Study Type

OBSERVATIONAL

Enrollment

2,985

Conditions

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * From 2011 to 2022, newly diagnosed NMOSD patients.. Exclusion Criteria: * Patients had a history of cancer * Patients had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Outcomes

Primary Outcomes

Relapse

Relapses were identified when patients were treated with one of the following interventions: intravenous steroids, immunoglobulin therapy, or plasma exchange.

Time frame: 1 year

Secondary Outcomes

Safety outcomes

Incidence of serious infection, fracture, cancer, myocardial infarction, stroke, depression, anxiety, dementia, and Parkinson's disease which defined as presence of ICD-10 codes.

Time frame: 6 months after start of ISTs

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.